Cargando…
Effect of body composition on survival benefit of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: A comparison with sorafenib therapy
AIM: Sorafenib is used as a first-line treatment for advanced hepatocellular carcinoma (HCC). However, hepatic arterial infusion chemotherapy (HAIC) has also gained acceptance, but only in Japan. We explored the role of body composition as a factor affecting the survival benefit of HAIC compared to...
Autores principales: | Saeki, Issei, Yamasaki, Takahiro, Maeda, Masaki, Hisanaga, Takuro, Iwamoto, Takuya, Matsumoto, Toshihiko, Hidaka, Isao, Ishikawa, Tsuyoshi, Takami, Taro, Sakaida, Isao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6564002/ https://www.ncbi.nlm.nih.gov/pubmed/31194789 http://dx.doi.org/10.1371/journal.pone.0218136 |
Ejemplares similares
-
Treatment strategies for advanced hepatocellular carcinoma: Sorafenib vs hepatic arterial infusion chemotherapy
por: Saeki, Issei, et al.
Publicado: (2018) -
Predictors of the Effect of Tolvaptan on the Prognosis of Cirrhosis
por: Iwamoto, Takuya, et al.
Publicado: (2016) -
A New Therapeutic Assessment Score for Advanced Hepatocellular Carcinoma Patients Receiving Hepatic Arterial Infusion Chemotherapy
por: Saeki, Issei, et al.
Publicado: (2015) -
Novel Therapeutic Strategy Using Interventional Radiology (IVR) for Hepatitis C Virus (HCV)-Related Decompensated Liver Cirrhosis: A Case Report
por: Iwamoto, Takuya, et al.
Publicado: (2019) -
Effects of an oral iron chelator, deferasirox, on advanced hepatocellular carcinoma
por: Saeki, Issei, et al.
Publicado: (2016)